A Multicenter, Randomized, Open Label Phase II Clinical Trial Evaluating the Efficacy and Safety of NTQ5082 Capsules in the Treatment of Patients With Paroxysmal Nocturnal Hemoglobinuria
Latest Information Update: 13 Jan 2025
Price :
$35 *
At a glance
- Drugs NTQ 5082 (Primary)
- Indications Paroxysmal nocturnal haemoglobinuria
- Focus Therapeutic Use
- Sponsors Nanjing Chia Tai Tianqing Pharmaceutical
- 13 Jan 2025 New trial record